333 related articles for article (PubMed ID: 34426026)
1. Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
Taylor SC; Hurst B; Martiszus I; Hausman MS; Sarwat S; Schapiro JM; Rowell S; Lituev A
Vaccine; 2021 Sep; 39(39):5688-5698. PubMed ID: 34426026
[TBL] [Abstract][Full Text] [Related]
2. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
Vandergaast R; Carey T; Reiter S; Lathrum C; Lech P; Gnanadurai C; Haselton M; Buehler J; Narjari R; Schnebeck L; Roesler A; Sevola K; Suksanpaisan L; Bexon A; Naik S; Brunton B; Weaver SC; Rafael G; Tran S; Baum A; Kyratsous CA; Peng KW; Russell SJ
mSphere; 2021 Jun; 6(3):e0017021. PubMed ID: 34077262
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
[TBL] [Abstract][Full Text] [Related]
4. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.
Takahashi M; Saito K; Ai T; Nojiri S; Khasawneh A; Paran FJ; Horiuchi Y; Takei S; Yamamoto T; Wakita M; Hiki M; Miida T; Naito T; Takahashi K; Tabe Y
PLoS One; 2023; 18(1):e0279779. PubMed ID: 36693058
[TBL] [Abstract][Full Text] [Related]
5. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.
Taylor SC; Hurst B; Charlton CL; Bailey A; Kanji JN; McCarthy MK; Morrison TE; Huey L; Annen K; DomBourian MG; Knight V
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33500361
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.
Lynch KL; Zhou S; Kaul R; Walker R; Wu AH
Clin Chem; 2022 May; 68(5):702-712. PubMed ID: 35018416
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
8. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
medRxiv; 2021 Aug; ():. PubMed ID: 34100029
[TBL] [Abstract][Full Text] [Related]
9. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
[TBL] [Abstract][Full Text] [Related]
10. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain.
Lee B; Ko JH; Lee KH; Kim YC; Song YG; Park YS; Baek YJ; Ahn JY; Choi JY; Song KH; Kim ES; Bae S; Kim SH; Jeong HW; Kim SW; Kwon KT; Kim SH; Jeong H; Kim B; Kim SS; Choi WS; Peck KR; Kang ES
Microbiol Spectr; 2022 Dec; 10(6):e0266922. PubMed ID: 36250875
[TBL] [Abstract][Full Text] [Related]
11. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
[TBL] [Abstract][Full Text] [Related]
12. Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.
Santos da Silva E; Servais JY; Kohnen M; Arendt V; Staub T; The Con-Vince Consortium ; The CoVaLux Consortium ; Krüger R; Fagherazzi G; Wilmes P; Hübschen JM; Ollert M; Perez-Bercoff D; Seguin-Devaux C
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834413
[TBL] [Abstract][Full Text] [Related]
13. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
14. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
16. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
18. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
Adams O; Andrée M; Hermsen D; Lübke N; Timm J; Schaal H; Müller L
J Virol Methods; 2022 Sep; 307():114569. PubMed ID: 35724697
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
20. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
